Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Antidepressant optimization, switching, and combination

17 evidence topics · 15 sources

CANMAT guideline: dose optimization, switching, and sequencing of adjunctive strategies

“Optimizing the antidepressant dose is an important first step.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Higher than minimal therapeutic doses are more effective (to a plateau around the equivalent of 50 mg of fluoxetine) but less well-tolerated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The evidence for the efficacy of switching antidepressants is inconsistent. Meta-analyses show that switching to another antidepressant is not superior to continuing the same one and there appears to be diminishing response rates for antidepressant monotherapy beyond the first switch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Moreover, RCTs directly comparing switching to adjunctive strategies have shown that adjunctive strategies have superior outcomes and often similar tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Hence, while balancing individual risks, benefits, and patient preference, CANMAT recommends that adjunctive strategies be considered earlier in the treatment algorithm, after limited response to the first or second antidepressant trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Switching should be considered first when there is no response to the initial antidepressant or when the first medication has troublesome side effects. Adjunctive strategies should be considered first when there is a partial response to the initial antidepressant and there are minimal or no tolerability issues with the first medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

VA/DoD guideline: evidence on dose escalation, switching, and antidepressant combinations
Switching after SSRI failure: remission and response with bupropion, sertraline, or venlafaxine